Sandra Mohamed Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sandra Mohamed Ahmed has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Abdelalim
Cairo University Stroke Center, Department of Neurology, Faculty of Medicine, Cairo University, Egypt (A.A., S.A., S.A.I.).
4 shared publications - Angelo Cascio Rizzo
Department of Neurology and Stroke Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
3 shared publications - Barbara Casolla
Stroke Unit, CHU Pasteur 2, Université Cote d’Azur, UMR2CA URRIS, Nice, France
3 shared publications - Basma Bahgat El Sayed
Clinical Neurophysiology Unit, Department of Neurology and Clinical Neurophysiology, Faculty of Medicine, Cairo University, Cairo, Egypt
3 shared publications Bernardo Antunes
Department of Neurology, Hospital de Santa Maria, Lisbon, Portugal
3 shared publications- Blanca Fuentes
Department of Neurology and Stroke Center, Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain
3 shared publications
Latest Publications
- 3 November 2026
- Published by SAGE Publications in International Journal of Stroke
Hemorrhagic transformation in breakthrough ischemic stroke: Clinical characteristics, outcomes, and anticoagulation resumption timing—insights from the ASPERA-R study
Background and Purpose: The timing of anticoagulation resumption in patients who experience ischemic stroke despite ongoing anticoagulation and develop hemorrhagic transformation (HT) remains uncertain. We aimed to describe the characteristics and outcomes of patients with HT after a breakthrough ischemic stroke and to explore the association between anticoagulation resumption timing and the model-predicted balance of recurrent ischemic and bleeding risks in this high-risk population. Methods: We analyzed data from patients with breakthrough ischemic stroke receiving anticoagulation therapy from the multicenter ASPERA-R registry. Analyses focused on patients with HT. HT was defined according to the Heidelberg Bleeding Classification based on brain imaging within 24 h and categorized as hemorrhagic infarction or parenchymal hematoma. Anticoagulation resumption and its timing were determined by treating clinicians and were not randomized. Landmark Cox regression models were used to evaluate recurrent ischemic events and moderate-to-severe bleeding after anticoagulation resumption. Restricted cubic spline models and exploratory net clinical benefit analyses integrating ischemic and bleeding risks were used to assess the relationship between anticoagulation resumption timing and model-predicted combined risk, overall and across clinically relevant subgroups. Results: Among 1555 patients with breakthrough ischemic stroke, 269 (17.3%) developed HT, of whom 170 (63.2%) resumed anticoagulation and contributed to the restart-timing analyses. At 90 days, patients with HT had higher crude rates of recurrent ischemic events (27.1% vs. 13.8%), moderate-to-severe bleeding (7.4% vs. 2.8%), and mortality (34.2% vs. 17.7%) compared with patients without HT. In landmark analyses, HT was not associated with recurrent ischemic events (hazard ratio (HR) = 1.42, 95% confidence interval (CI) = 0.85–2.37) but remained strongly associated with moderate-to-severe bleeding (HR = 3.39, 95% CI = 1.61–7.13). Exploratory net clinical benefit analyses showed that the model-predicted combined risk reached its nadir at approximately 10 days after stroke in the overall HT population, with substantial uncertainty around this estimate. Conclusions: HT is a marker of poor prognosis in patients with breakthrough ischemic stroke, with an increased risk of bleeding after anticoagulation resumption. Among selected patients who resumed anticoagulation, exploratory modeling suggested that the combined predicted ischemic and bleeding risk reached its nadir at approximately 10 days after stroke. Given the non-randomized treatment timing and potential for treatment-selection bias, this estimate is hypothesis-generating and requires prospective validation.
- 3 November 2026
- Published by SAGE Publications in International Journal of Stroke
Hemorrhagic transformation in breakthrough ischemic stroke: Clinical characteristics, outcomes, and anticoagulation resumption timing—insights from the ASPERA-R study
Background and Purpose: The timing of anticoagulation resumption in patients who experience ischemic stroke despite ongoing anticoagulation and develop hemorrhagic transformation (HT) remains uncertain. We aimed to describe the characteristics and outcomes of patients with HT after a breakthrough ischemic stroke and to explore the association between anticoagulation resumption timing and the model-predicted balance of recurrent ischemic and bleeding risks in this high-risk population. Methods: We analyzed data from patients with breakthrough ischemic stroke receiving anticoagulation therapy from the multicenter ASPERA-R registry. Analyses focused on patients with HT. HT was defined according to the Heidelberg Bleeding Classification based on brain imaging within 24 h and categorized as hemorrhagic infarction or parenchymal hematoma. Anticoagulation resumption and its timing were determined by treating clinicians and were not randomized. Landmark Cox regression models were used to evaluate recurrent ischemic events and moderate-to-severe bleeding after anticoagulation resumption. Restricted cubic spline models and exploratory net clinical benefit analyses integrating ischemic and bleeding risks were used to assess the relationship between anticoagulation resumption timing and model-predicted combined risk, overall and across clinically relevant subgroups. Results: Among 1555 patients with breakthrough ischemic stroke, 269 (17.3%) developed HT, of whom 170 (63.2%) resumed anticoagulation and contributed to the restart-timing analyses. At 90 days, patients with HT had higher crude rates of recurrent ischemic events (27.1% vs. 13.8%), moderate-to-severe bleeding (7.4% vs. 2.8%), and mortality (34.2% vs. 17.7%) compared with patients without HT. In landmark analyses, HT was not associated with recurrent ischemic events (hazard ratio (HR) = 1.42, 95% confidence interval (CI) = 0.85–2.37) but remained strongly associated with moderate-to-severe bleeding (HR = 3.39, 95% CI = 1.61–7.13). Exploratory net clinical benefit analyses showed that the model-predicted combined risk reached its nadir at approximately 10 days after stroke in the overall HT population, with substantial uncertainty around this estimate. Conclusions: HT is a marker of poor prognosis in patients with breakthrough ischemic stroke, with an increased risk of bleeding after anticoagulation resumption. Among selected patients who resumed anticoagulation, exploratory modeling suggested that the combined predicted ischemic and bleeding risk reached its nadir at approximately 10 days after stroke. Given the non-randomized treatment timing and potential for treatment-selection bias, this estimate is hypothesis-generating and requires prospective validation.
- 29 October 2026
- Published by Wolters Kluwer Health in Stroke
Impact of Inflammatory Burden on Outcomes After Breakthrough Ischemic Stroke: Insights From the ASPERA-R Study
BACKGROUND: Patients with atrial fibrillation who experience ischemic stroke despite oral anticoagulation (breakthrough stroke) remain at high risk of recurrent vascular events and death. Although inflammation has been associated with thromboembolic risk, its prognostic role in breakthrough stroke remains unclear. We investigated whether a composite inflammatory burden index was associated with adverse outcomes after breakthrough ischemic stroke. METHODS: We conducted a multicenter retrospective cohort study of consecutive patients with breakthrough ischemic stroke from the ASPERA-R registry. Inflammatory burden was assessed using admission neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune–inflammation index, and C-reactive protein. Biomarkers were log-transformed, standardized using Z scores, and combined into a composite inflammatory burden index. Patients were classified as having high (upper tertile) or lower inflammatory burden (lower 2 tertiles). Outcomes included new 90-day ischemic events (recurrent ischemic stroke, transient ischemic attack, or systemic embolism), 24-hour hemorrhagic transformation, and 90-day moderate-to-severe bleeding, intracranial hemorrhage, and mortality. Inverse probability of treatment weighting accounted for center, demographics, vascular risk factors and comorbidities, anticoagulation, competing stroke causes, baseline National Institutes of Health Stroke Scale, prestroke modified Rankin Scale, and time to blood collection. RESULTS: Among 1649 patients enrolled in ASPERA-R, 671 patients from 14 centers had complete biomarker data (median age, 80.1 years [interquartile range, 73.5–85.5]; 52.3% female). Of these, 223 (33.2%) had high inflammatory burden, and 448 (66.8%) had lower inflammatory burden. After weighting, high inflammatory burden was associated with increased risks of ischemic events at 90 days (hazard ratio, 1.53 [95% CI, 1.02–2.30]), all-cause mortality (hazard ratio, 1.70 [95% CI, 1.17–2.47]), moderate-to-severe bleeding (hazard ratio, 2.92 [95% CI, 1.04–8.17]), and hemorrhagic transformation at 24 hours (odds ratio, 2.18 [95% CI, 1.43–3.33]). CONCLUSIONS: In breakthrough ischemic stroke, high inflammatory burden was associated with increased risks of recurrent ischemic events, mortality, hemorrhagic transformation, and major bleeding. A composite of routinely available inflammatory biomarkers may help identify patients with higher residual vascular risk.
- 29 October 2026
- Published by Wolters Kluwer Health in Stroke
Impact of Inflammatory Burden on Outcomes After Breakthrough Ischemic Stroke: Insights From the ASPERA-R Study
BACKGROUND: Patients with atrial fibrillation who experience ischemic stroke despite oral anticoagulation (breakthrough stroke) remain at high risk of recurrent vascular events and death. Although inflammation has been associated with thromboembolic risk, its prognostic role in breakthrough stroke remains unclear. We investigated whether a composite inflammatory burden index was associated with adverse outcomes after breakthrough ischemic stroke. METHODS: We conducted a multicenter retrospective cohort study of consecutive patients with breakthrough ischemic stroke from the ASPERA-R registry. Inflammatory burden was assessed using admission neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune–inflammation index, and C-reactive protein. Biomarkers were log-transformed, standardized using Z scores, and combined into a composite inflammatory burden index. Patients were classified as having high (upper tertile) or lower inflammatory burden (lower 2 tertiles). Outcomes included new 90-day ischemic events (recurrent ischemic stroke, transient ischemic attack, or systemic embolism), 24-hour hemorrhagic transformation, and 90-day moderate-to-severe bleeding, intracranial hemorrhage, and mortality. Inverse probability of treatment weighting accounted for center, demographics, vascular risk factors and comorbidities, anticoagulation, competing stroke causes, baseline National Institutes of Health Stroke Scale, prestroke modified Rankin Scale, and time to blood collection. RESULTS: Among 1649 patients enrolled in ASPERA-R, 671 patients from 14 centers had complete biomarker data (median age, 80.1 years [interquartile range, 73.5–85.5]; 52.3% female). Of these, 223 (33.2%) had high inflammatory burden, and 448 (66.8%) had lower inflammatory burden. After weighting, high inflammatory burden was associated with increased risks of ischemic events at 90 days (hazard ratio, 1.53 [95% CI, 1.02–2.30]), all-cause mortality (hazard ratio, 1.70 [95% CI, 1.17–2.47]), moderate-to-severe bleeding (hazard ratio, 2.92 [95% CI, 1.04–8.17]), and hemorrhagic transformation at 24 hours (odds ratio, 2.18 [95% CI, 1.43–3.33]). CONCLUSIONS: In breakthrough ischemic stroke, high inflammatory burden was associated with increased risks of recurrent ischemic events, mortality, hemorrhagic transformation, and major bleeding. A composite of routinely available inflammatory biomarkers may help identify patients with higher residual vascular risk.
- 19 June 2026
- Published by SAGE Publications in International Journal of Stroke
Early versus Late starting of Direct Oral Anticoagulants after breakthrough ischemic stroke: A Target Trial Analysis from the ASPERA-R Study
Background and Purpose.: Randomized trials support early initiation of direct oral anticoagulants (DOACs) after atrial fibrillation (AF)–related ischemic stroke, but patients with breakthrough ischemic stroke occurring despite ongoing anticoagulation have been largely under-represented. We evaluated the effectiveness and safety of early versus delayed DOAC initiation after breakthrough ischemic stroke. Methods.: We performed a target trial emulation comparing early versus delayed DOAC initiation in patients with breakthrough ischemic stroke. Treatment strategies were prespecified using severity-adapted timing thresholds based on baseline National Institutes of Health Stroke Scale (NIHSS) scores. The study population was drawn from the retrospective arm of the international, multicentre ASPERA study and included patients with AF who experienced an ischemic stroke while receiving continuous anticoagulation. To emulate random assignment and avoid immortal time bias, a cloning–censoring–weighting approach with inverse probability weighting was applied. Primary outcomes were 90-day new ischemic events and moderate-to-severe bleeding. Risk ratios (RRs), absolute risk differences (RDs), and hazard ratios (HRs) were estimated using weighted regression and Cox models. Results.: Among 833 patients (median age 81 years), 336 were assigned to early and 497 to delayed DOAC initiation. At 90 days, early initiation was associated with a lower risk of new ischemic events (RR 0.44, 95% CI 0.21–0.90; RD −3.64%, 95% CI −6.40 to −0.87; HR 0.43, 95% CI 0.21–0.91). Moderate-to-severe bleeding occurred less frequently with early initiation (RR 0.10, 95% CI 0.01–0.76). Early initiation was also associated with lower 90-day all-cause and vascular mortality. A Net Early Benefit Score integrating ischemic and bleeding risks was positive across all NIHSS strata. Conclusions.: In patients with breakthrough ischemic stroke, early severity-adapted DOAC initiation was associated with lower risks of recurrent ischemic events and mortality at 90 days without an increase in major bleeding. These findings support early anticoagulation initiation in this high-risk population.
- 19 June 2026
- Published by SAGE Publications in International Journal of Stroke
Early versus Late starting of Direct Oral Anticoagulants after breakthrough ischemic stroke: A Target Trial Analysis from the ASPERA-R Study
Background and Purpose.: Randomized trials support early initiation of direct oral anticoagulants (DOACs) after atrial fibrillation (AF)–related ischemic stroke, but patients with breakthrough ischemic stroke occurring despite ongoing anticoagulation have been largely under-represented. We evaluated the effectiveness and safety of early versus delayed DOAC initiation after breakthrough ischemic stroke. Methods.: We performed a target trial emulation comparing early versus delayed DOAC initiation in patients with breakthrough ischemic stroke. Treatment strategies were prespecified using severity-adapted timing thresholds based on baseline National Institutes of Health Stroke Scale (NIHSS) scores. The study population was drawn from the retrospective arm of the international, multicentre ASPERA study and included patients with AF who experienced an ischemic stroke while receiving continuous anticoagulation. To emulate random assignment and avoid immortal time bias, a cloning–censoring–weighting approach with inverse probability weighting was applied. Primary outcomes were 90-day new ischemic events and moderate-to-severe bleeding. Risk ratios (RRs), absolute risk differences (RDs), and hazard ratios (HRs) were estimated using weighted regression and Cox models. Results.: Among 833 patients (median age 81 years), 336 were assigned to early and 497 to delayed DOAC initiation. At 90 days, early initiation was associated with a lower risk of new ischemic events (RR 0.44, 95% CI 0.21–0.90; RD −3.64%, 95% CI −6.40 to −0.87; HR 0.43, 95% CI 0.21–0.91). Moderate-to-severe bleeding occurred less frequently with early initiation (RR 0.10, 95% CI 0.01–0.76). Early initiation was also associated with lower 90-day all-cause and vascular mortality. A Net Early Benefit Score integrating ischemic and bleeding risks was positive across all NIHSS strata. Conclusions.: In patients with breakthrough ischemic stroke, early severity-adapted DOAC initiation was associated with lower risks of recurrent ischemic events and mortality at 90 days without an increase in major bleeding. These findings support early anticoagulation initiation in this high-risk population.
- 23 April 2026
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 267, 109430
Development and expert refinement of a stratified framework for progression independent of relapse activity (PIRA) in multiple sclerosis
- 23 April 2026
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 267, 109430
Development and expert refinement of a stratified framework for progression independent of relapse activity (PIRA) in multiple sclerosis
- 21 February 2026
- Published by Wiley in Physiotherapy Research International
- Vol. 31 (2) , e70175
Impact of High Tone Power Therapy on Lower Limb Spasticity and Gait Speed in Patients at Least Six Months Post‐Stroke: A Randomized Controlled Trial
Introduction: The effective management of spasticity and improving functional mobility continue to pose challenges to physiotherapy management. This research designed to compare the impact of combining high‐tone power therapy with physical therapy program versus physical therapy alone on lower limb spasticity and gait speed in chronic (≥ 6 months) stroke, non‐obese, middle‐aged male patients. Material and Methods: Thirty‐four eligible male patients were randomly assigned to 2 groups equal in number: treatment (G1) and control (G2). The subjects in the treatment group received 30 min of real high‐tone power therapy stimulation (HTT), followed by 30 min of selected physical therapy program. The control group received only 1 h of selected physical therapy program (3 days per week for 3 months). Spasticity was measured by Modified Ashworth scale (MAS) and Neurophysiological studies (H/M ratio), self‐selected comfortable walking speed (SSCWS) and fastest walking speed (FWS) were measured by 10 m walk test (10 MWT) and assessed for both groups at baseline and after intervention. Results: Post treatment, between‐group analysis showed that G1 (HTT + physical therapy) demonstrated significant improvements ( p < 0.05) compared to G2 (physical therapy alone) in spasticity (MAS: p = 0.017, H/M ratio: p = 0.0001) and gait speed (10MWT‐SSCWS: p = 0.0001, 10MWT‐FWS: p = 0.0001). Within group analysis indicated that there was no significant decrease ( p > 0.05) in MAS ( p = 0.589), H/M ratio ( p = 0.806), 10MWT‐SSCWD ( p = 0.136), and 10MWT‐FWS ( p = 0.287) within the control group (G2). Conclusions: The combined program of high‐tone power therapy (HTT) for 30 min followed by 30 min of physical therapy program has superior effects in improving spasticity and gait speed in non‐obese, middle‐aged male patients with chronic stroke compared to the physical therapy program alone. While these findings support the potential value of the combined approach, the difference in the therapeutic program between the 2 groups and the absence of a sham control group prevent determining the specific contribution of the HTT component. Future dose‐matched and sham‐controlled trials are required to clarify the independent therapeutic effect of HTT. Trial Registration: Prospectively registered with ClinicalTrials.gov as Registry ID: (NCT06562530)
- 21 February 2026
- Published by Wiley in Physiotherapy Research International
- Vol. 31 (2) , e70175
Impact of High Tone Power Therapy on Lower Limb Spasticity and Gait Speed in Patients at Least Six Months Post‐Stroke: A Randomized Controlled Trial
Introduction: The effective management of spasticity and improving functional mobility continue to pose challenges to physiotherapy management. This research designed to compare the impact of combining high‐tone power therapy with physical therapy program versus physical therapy alone on lower limb spasticity and gait speed in chronic (≥ 6 months) stroke, non‐obese, middle‐aged male patients. Material and Methods: Thirty‐four eligible male patients were randomly assigned to 2 groups equal in number: treatment (G1) and control (G2). The subjects in the treatment group received 30 min of real high‐tone power therapy stimulation (HTT), followed by 30 min of selected physical therapy program. The control group received only 1 h of selected physical therapy program (3 days per week for 3 months). Spasticity was measured by Modified Ashworth scale (MAS) and Neurophysiological studies (H/M ratio), self‐selected comfortable walking speed (SSCWS) and fastest walking speed (FWS) were measured by 10 m walk test (10 MWT) and assessed for both groups at baseline and after intervention. Results: Post treatment, between‐group analysis showed that G1 (HTT + physical therapy) demonstrated significant improvements ( p < 0.05) compared to G2 (physical therapy alone) in spasticity (MAS: p = 0.017, H/M ratio: p = 0.0001) and gait speed (10MWT‐SSCWS: p = 0.0001, 10MWT‐FWS: p = 0.0001). Within group analysis indicated that there was no significant decrease ( p > 0.05) in MAS ( p = 0.589), H/M ratio ( p = 0.806), 10MWT‐SSCWD ( p = 0.136), and 10MWT‐FWS ( p = 0.287) within the control group (G2). Conclusions: The combined program of high‐tone power therapy (HTT) for 30 min followed by 30 min of physical therapy program has superior effects in improving spasticity and gait speed in non‐obese, middle‐aged male patients with chronic stroke compared to the physical therapy program alone. While these findings support the potential value of the combined approach, the difference in the therapeutic program between the 2 groups and the absence of a sham control group prevent determining the specific contribution of the HTT component. Future dose‐matched and sham‐controlled trials are required to clarify the independent therapeutic effect of HTT. Trial Registration: Prospectively registered with ClinicalTrials.gov as Registry ID: (NCT06562530)
- Open Access
- 15 November 2023
- Published by National Medical Research Center For Rehabilitation And Balneology in Bulletin of Rehabilitation Medicine
- Vol. 22 (5)
Expiratory Muscle Training Versus Functional Electrical Stimulation on Pulmonary and Swallowing Functions in Acute Stroke Patients
INTRODUCTION. Post-stroke dysphagia is reported in 30–50 % of stroke population. It increases mortality rate and leads to serious complications such as expiratory muscle affection which is a major cause of defective swallowing and ineffective airway protection. Expiratory muscle strength training (EMST) and functional electrical stimulation (FES) are recommended techniques to improve expiratory muscles performance. AIM. To compare the effect of EMST to that of FES on pulmonary and swallowing functions in acute stroke patients. MATERIAL AND METHODS. Seventy-two patients with post-stroke dysphagia were divided into two groups. Both groups received traditional dysphagia treatment. In addition, the first group received EMST and the second received neck and abdominal FES. Pulmonary functions were measured before and after in form of forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio and peak expiratory flow (PEF), and arterial blood gases (ABG) while the Gugging Swallowing Scale (GUSS) was used as an indicator of swallowing function results of both groups were compared after one month of treatment. RESULTS. The post-treatment GUSS, FVC, FEV1 and PEF of the EMST group showed more significant increase compared to the FES group (p 0.05) with no significant differences in FEV1/FVC (p 0.05). Regarding ABG, there was more significant decrease in PaCO2 and HCO3 of EMST group compared to FES group (p 0.01). CONCLUSION. EMST was more effective than FES when it comes to improving expiratory and swallowing functions in patients with post-stroke dysphagia.
- 15 November 2023
- Published by National Medical Research Center For Rehabilitation And Balneology in Bulletin of Rehabilitation Medicine
- Vol. 22 (5)
Open AccessExpiratory Muscle Training Versus Functional Electrical Stimulation on Pulmonary and Swallowing Functions in Acute Stroke Patients
INTRODUCTION. Post-stroke dysphagia is reported in 30–50 % of stroke population. It increases mortality rate and leads to serious complications such as expiratory muscle affection which is a major cause of defective swallowing and ineffective airway protection. Expiratory muscle strength training (EMST) and functional electrical stimulation (FES) are recommended techniques to improve expiratory muscles performance. AIM. To compare the effect of EMST to that of FES on pulmonary and swallowing functions in acute stroke patients. MATERIAL AND METHODS. Seventy-two patients with post-stroke dysphagia were divided into two groups. Both groups received traditional dysphagia treatment. In addition, the first group received EMST and the second received neck and abdominal FES. Pulmonary functions were measured before and after in form of forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio and peak expiratory flow (PEF), and arterial blood gases (ABG) while the Gugging Swallowing Scale (GUSS) was used as an indicator of swallowing function results of both groups were compared after one month of treatment. RESULTS. The post-treatment GUSS, FVC, FEV1 and PEF of the EMST group showed more significant increase compared to the FES group (p 0.05) with no significant differences in FEV1/FVC (p 0.05). Regarding ABG, there was more significant decrease in PaCO2 and HCO3 of EMST group compared to FES group (p 0.01). CONCLUSION. EMST was more effective than FES when it comes to improving expiratory and swallowing functions in patients with post-stroke dysphagia.
- Open Access
- 10 October 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 56, 103324
The MuSC-19 study: The Egyptian cohort
- 10 October 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 56, 103324
Open AccessThe MuSC-19 study: The Egyptian cohort
- 1 November 2017
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 34 (6) , 553-554
Reply to Considerations About “Carpal Tunnel Syndrome Grading Using High-Resolution Ultrasonography”
- 1 November 2017
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 34 (6) , 553-554
Reply to Considerations About “Carpal Tunnel Syndrome Grading Using High-Resolution Ultrasonography”
- 1 July 2017
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 34 (4) , 353-358
Carpal Tunnel Syndrome Grading Using High-Resolution Ultrasonography
Purpose: Carpal tunnel syndrome (CTS) is a common entrapment neuropathy of the wrist. The diagnosis of CTS has been a concern for physicians for a long time. The aim of this study is to evaluate the use of the median nerve (MN) cross-sectional area (CSA) in the wrist compared with the CSA in the forearm to grade the severity of CTS in Egyptian patients. Methods: The CSAs of the MN in the wrist and forearm were measured in 72 wrists that were diagnosed with CTS via nerve conduction studies and 80 healthy wrists. The CTS group was subdivided into three subgroups (mild, moderate, and severe CTS). The ratio of the CSA of the MN in the wrist to that in the forearm was used to calculate cutoff values for CTS grading. Results: There were positive correlations between the CSAs of the MN in the wrist and MN conduction latency. At a wrist–forearm ratio of 1.7, the high-resolution ultrasonography showed 96.1% accuracy in the detection of CTS. Conclusions: High-resolution ultrasonography can be used in CTS grading.
- 1 July 2017
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 34 (4) , 353-358
Carpal Tunnel Syndrome Grading Using High-Resolution Ultrasonography
Purpose: Carpal tunnel syndrome (CTS) is a common entrapment neuropathy of the wrist. The diagnosis of CTS has been a concern for physicians for a long time. The aim of this study is to evaluate the use of the median nerve (MN) cross-sectional area (CSA) in the wrist compared with the CSA in the forearm to grade the severity of CTS in Egyptian patients. Methods: The CSAs of the MN in the wrist and forearm were measured in 72 wrists that were diagnosed with CTS via nerve conduction studies and 80 healthy wrists. The CTS group was subdivided into three subgroups (mild, moderate, and severe CTS). The ratio of the CSA of the MN in the wrist to that in the forearm was used to calculate cutoff values for CTS grading. Results: There were positive correlations between the CSAs of the MN in the wrist and MN conduction latency. At a wrist–forearm ratio of 1.7, the high-resolution ultrasonography showed 96.1% accuracy in the detection of CTS. Conclusions: High-resolution ultrasonography can be used in CTS grading.
- 1 March 2016
- Published by Elsevier in Clinical Neurophysiology
- Vol. 127 (3) , e121
ID 248 – Therapeutic role of repetitive peripheral magnetic stimulation in carpal tunnel syndrome
- 1 March 2016
- Published by Elsevier in Clinical Neurophysiology
- Vol. 127 (3) , e121
ID 248 – Therapeutic role of repetitive peripheral magnetic stimulation in carpal tunnel syndrome